WeiSongMD

Hematology & Oncology physician in Pottstown affiliated with multiple hospitals in the area, including Phoenixville Hospital and Pottstown Memorial Medical Center.

Join to view full profile

Dr. Song is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Song's full profile

Already have an account?

Office
1600 E High St
Pottstown, PA 19464
Phone+1 610-327-7555

Fax+1 610-705-5616
Is this information wrong?

Education & Training

Temple University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
Mercy Catholic Medical CenterResidency, Internal Medicine, 1995 - 1998
Shanghai Medical UniversityClass of 1987

Certifications & Licensure

PA State Medical License 1995 - 2024
CA State Medical License 2018 - 2024
NJ State Medical License 2001 - 2003
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 17
Completed
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Terminated
Phase 2
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21
Active, not recruiting
Phase 2
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

11 citations
Urine DNA biomarkers for hepatocellular carcinoma screening.
Amy K Kim, James P Hamilton, Selena Y Lin, Ting-Tsung Chang, Hie-Won Hann, Chi-Tan Hu, Yue Lou, Yih-Jyh Lin, Terence P Gade, Grace Park, Harry Luu, Tai-Jung Lee, Jerem...> ;British Journal of Cancer. 2022 Jun 1
Prospective Comparison of Geriatric Assessment and Provider's Assessment of Older Adults With Metastatic Breast Cancer in the Community.
Rino S Seedor, Caitlin R Meeker, Bianca Lewis, Elizabeth A Handorf, Kelly A Filchner, Ramya Varadarajan, Jack Hensold, Aruna Padmanabhan, Benjamin Negin, Kenneth Blank...> ;The Oncologist. 2022 Mar 4
6 citations
Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patien...
M. K. Gibson, Paul J. Catalano, Lawrence Kleinberg, Charles A. Staley, Elizabeth A. Montgomery, Antonio Jimeno, Wei Frank Song, Mary F. Mulcahy, Lawrence Leichman, Al ...> ;The Oncologist. 2020 Jan 1
Urine-Based Liquid Biopsy for Nonurological Cancers.
Jain, S.,Lin, S. Y.,Song, W.,Su, Y. H.> ;Genet Test Mol Biomarkers. 2019 Apr 16
Development and Evaluation of Novel Statistical Methods in Urine Biomarker-Based Hepatocellular Carcinoma Screening.
Wang, J.,Jain, S.,Chen, D.,Song, W.,Hu, C. T.,Su, Y. H.> ;Sci Rep. 2018 Mar 02
12 citations
The Women's wellness after cancer program: a multisite, single-blinded, randomised controlled trial protocol.
Debra Anderson, Charrlotte Seib, Dian Tjondronegoro, Jane Turner, Leanne Monterosso, Amanda McGuire, Janine Porter-Steele, Wei Song, Patsy Yates, Neil King, Leonie You...> ;BMC Cancer. 2017 Feb 3
Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis.
Jain, S.,Xie, L.,Boldbaatar, B.,Lin, S. Y.,Hamilton, J. P.,Meltzer, S. J.,Chen, S. H.,Hu, C. T.,Block, T. M.,Song, W.,Su, Y. H.> ;Hepatol. Res.. 2014 Nov 11
DNA markers in molecular diagnostics for hepatocellular carcinoma.
Su, Y. H.,Lin, S. Y.,Song, W.,Jain, S.> ;Expert Rev. Mol. Diagn.. 2014 Aug 08
Impact of the Location of CpG Methylation within the GSTP1 Gene on Its Specificity as a DNA Marker for Hepatocellular Carcinoma.
Jain, S., Chen, S., Chang, K. C., Lin, Y. J., Hu, C. T., Boldbaatar, B., Hamilton, J. P., Lin, S. Y., Chang, T. T., Chen, S. H., Song, W., Meltzer, S. J., Block, T. M....> ;PLoS ONE. 2012
Join now to see all